Background[1-3]
Fructokinase-6 phosphate antibodies are immune proteins that specifically bind to fructokinase-6 phosphate. 6-Phosphofructokinase antibody is a high-purity immune protein obtained by injecting 6-phosphate fructokinase into sterile animals for systemic immunization and then purifying them from their serum. 6-Phosphofructokinase is an allosteric enzyme and a key enzyme in the glycolysis pathway. The enzyme is composed of 4 subunits and is a tetramer. The relative molecular weight is 340 000. ATP/AMP and H+ concentration have a significant impact on the enzyme activity. It is currently believed that 6-phosphofructokinase has the lowest catalytic efficiency, so it is the rate-limiting enzyme of glycolysis.
Apply[4][5]
For research on the expression, clinical significance and role of 6-phosphofructose-2-kinase in colorectal cancer
Colorectal cancer (CRC) is one of the most common malignant tumors of the digestive system in humans. In recent years, the incidence and mortality of CRC have shown a significant upward trend. The invasive growth and distant metastasis of malignant tumors require adequate nutrition and energy metabolism. Therefore, tumor cells need to adjust their own energy metabolism to meet the needs of their rapid growth and invasion and metastasis, that is, metabolic reprogramming, in which “aerobic glycolysis” ” is the main way of glucose metabolism in tumors. Inhibiting glycolysis can significantly inhibit tumor proliferation, invasion and metastasis.
6-Phosphofructokinase-2/fructose bisphosphatase-2 (PFKFB) catalyzes the synthesis reaction Fru-6-P+ATP→Fru-2,6 -BP+ADP and hydrolysis reaction Fru-2,6-BP+H2O→Fru-6-P+P. 2,6-Fructose bisphosphate is an allosteric activator of 6-phosphofructo-1-kinase (PFK-1) and the most effective stimulator of glycolysis. The expression of PFKFB in CRC and paracancerous tissues was detected, the expression correlation between PFKFB and HIF-1α was evaluated, and its relationship with clinical pathological characteristics and prognosis of patients was explored, and the most relevant prognostic factor for CRC patients was selected. gene as the target gene, and observe the effects of knockdown of the target gene on the glucose metabolism, proliferation, invasion and metastasis ability of CRC cells in vitro, providing new strategies and ideas for clinical prognostic indicators and glucose metabolism targeted therapy for CRC patients. Objective To detect the expression of 6-phosphofructose-2-kinase (PFKFB) in CRC and paracancerous tissues, and explore its clinical significance and effect on glucose metabolism, proliferation, invasion and metastasis of CRC cells in vitro.
